In a preclinical study published in Cancer Research, researchers from the University of Texas MD Anderson Cancer Center have ...

Recent research is helping to expand the potential biomarker landscape in non–small cell lung cancer (NSCLC) and may soon ...

Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 ...

A proprietary monoclonal antibody targeting an inhibitory immune checkpoint pathway had favorable safety and tolerability in ...

The biotechnology company administered its IL-1RAP antibody to the initial participant in early-stage testing for ...

Researchers found that FcγR signaling in microglia may drive neuron loss in Parkinson’s disease models. Blocking FcγR ...

AnaptysBio is splitting into a high-margin royalty company and a pipeline-focused biopharma, each with distinct valuation ...

Singlomics Biopharmaceuticals, an innovative clinical-stage biopharmaceutical company focused on the discovery and development of antibody therapeutics for oncology, inflammation, and autoimmune ...

Patients with advanced HER2-negative gastric cancer respond differently to immunotherapy based on whether they are Asian or ...

A metabolic enzyme found in the support cells surrounding tumors may hold the key to predicting which cancer patients will ...

In patients with resected stage III mismatch repair-deficient colon cancer, adjuvant atezolizumab plus standard chemotherapy ...

L1, termed IB101, which was found to form a defined binding pocket that precisely positions the active moiety in a reactive conformation.